[Skip to Navigation]
Comment & Response
June 27, 2022

Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply

Author Affiliations
  • 1Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • 2Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom
  • 3Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
JAMA Neurol. 2022;79(7):726-727. doi:10.1001/jamaneurol.2022.1604

In Reply We thank Gros et al for their interest and their thoughtful comments on our article.1 In response, we described monoamine oxidase B inhibitors (MAOBIs) and catechol-O-methyltransferase inhibitors (COMTIs) as dopamine degradation inhibitors in the PD MED protocol. This was amended during the article review process to dopamine reuptake inhibitors. We have no strong views on best terminology; the key point in the trial design was that these 2 classes of drug were, and remain, the main alternatives to dopamine agonists as adjuvant treatment for motor complications that are unresponsive to levodopa dose escalation.

Add or change institution